Biomarker-Based Immunoassays Market Poised to Reach $11.55 Billion by 2030, Driven by AI Integration and Rising Cancer Incidence
Key Insights
The global biomarker-based immunoassays market is projected to grow from $6.6 billion in 2025 to $11.55 billion by 2030, at a CAGR of 11.9%.
Rising cancer (search) incidence is a key growth driver, with the WHO projecting over 35 million new cancer cases by 2050, a 77% increase from 2022.
AI-driven biomarker interpretation, multiplex immunoassay platforms, and cloud-integrated systems are reshaping the diagnostic landscape.
The global biomarker-based immunoassays market is on a robust growth trajectory, with its valuation expected to climb from $6.6 billion in 2025 to $11.55 billion by 2030, reflecting a compound annual growth rate (CAGR) of 11.9%, according to a new market report from The Business Research Company (search). The market reached an estimated $7.37 billion in 2026, growing at a CAGR of 11.6% from the prior year.
This expansion is fueled by converging forces: the rising prevalence of chronic diseases, accelerating demand for early diagnostic testing, and the increasing integration of artificial intelligence in biomarker data analysis. Biomarker-based immunoassays—analytical methods that rely on antigen-antibody interactions to detect and quantify specific biological markers such as proteins, hormones, or other molecules—are becoming indispensable tools in clinical diagnostics and biomedical research due to their high sensitivity and specificity.
Cancer (search) Incidence as a Primary Growth Catalyst
One of the most significant drivers behind the market's expansion is the escalating global burden of cancer (search). In February 2024, the World Health Organization reported that new cancer cases are projected to surpass 35 million by 2050, representing a 77% increase from the approximately 20 million cases recorded in 2022. This surge, linked largely to aging populations, underscores the critical need for advanced diagnostic tools capable of enabling early detection, precise disease monitoring, and personalized therapy guidance through accurate identification of cancer-specific markers.
Biomarker-based immunoassays contribute meaningfully to oncology management by facilitating the detection of cancer (search) at earlier, more treatable stages and by guiding treatment decisions based on individual tumor biology.
Key Innovations Reshaping the Market
Several technological trends are redefining the biomarker-based immunoassays landscape. AI-driven biomarker interpretation and predictive modeling are enhancing diagnostic accuracy, allowing clinicians to extract more meaningful insights from complex datasets. The emergence of multiplex immunoassay platforms enables the simultaneous detection of multiple biomarkers, significantly boosting laboratory efficiency and throughput.
Cloud-integrated immunoassay systems are enabling centralized management of diagnostic data, while laboratory automation and robotic sample processing are accelerating high-throughput testing workflows. Additionally, next-generation point-of-care immunoassay devices are gaining traction, providing rapid clinical diagnostics across diverse healthcare settings, including remote and resource-limited environments.
The broader adoption of personalized medicine and precision diagnostics, coupled with rising investments in pharmaceutical research and drug discovery, is expected to further propel market growth through the end of the decade.
Regional Dynamics
North America held the largest share of the biomarker-based immunoassays market in 2025, a position attributed to the region's advanced healthcare infrastructure, strong presence of diagnostic laboratories, and early adoption of innovative testing technologies. Meanwhile, the Asia-Pacific region is forecast to experience the fastest growth during the upcoming period, driven by expanding healthcare access, increasing disease awareness, and growing investment in diagnostic capabilities across emerging economies.
The comprehensive market analysis spans regions including Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, as well as the Middle East and Africa, reflecting the global nature of demand for biomarker-based diagnostic solutions.
Broader Biomarkers Market Context
The growth in biomarker-based immunoassays aligns with broader trends in the overall biomarkers market. According to a separate analysis by MarketsandMarkets (search), the global biomarkers market is projected to grow from approximately $67.95 billion in 2026 to $112.10 billion by 2031, at a CAGR of 10.5%. Within this larger market, immunoassays remain a core technology alongside next-generation sequencing, PCR, mass spectrometry, and chromatography.
The consumables segment held the largest share of the broader biomarkers market at 73.4% in 2025, while safety biomarkers dominated by type with a 48.5% share. Genomics accounted for the largest share by research area, reflecting the field's capacity for comprehensive analysis of DNA, RNA, and genomic variants associated with disease.